New drug tested to fight common hair loss
NCT ID NCT06393452
Summary
This study tested an experimental topical treatment called PP405 for common pattern hair loss (androgenetic alopecia). It involved 78 adults to check the treatment's safety, how much of the drug gets into the body, and its early effects. The trial had two parts: a 28-day blinded comparison against a placebo gel, followed by a 3-month open-label extension.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Dermatology & Clinical Research Institute
Encinitas, California, 92024, United States
-
Clinical Trials Research Institute
Thousand Oaks, California, 91320, United States
-
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250, United States
-
DermResearch
Austin, Texas, 78759, United States
-
Jordan Valley Dermatology Center
South Jordan, Utah, 84095, United States
-
Minnesota Clinical Study Center
New Brighton, Minnesota, 55112, United States
-
Stride Clinical Research LLC
Sugar Land, Texas, 77479, United States
-
Virginia Clinical Research, Inc.
Norfolk, Virginia, 23502, United States
Conditions
Explore the condition pages connected to this study.